🧬 Rethinking Diabetes: What the YODA Study Reveals About a Missing Diagnosis

July 2025

When we think of diabetes, we usually picture two types:

• Type 1 – an autoimmune attack on insulin-producing cells, mostly in children

• Type 2 – linked to insulin resistance, often in adults with overweight or obesity

But what if there’s another kind—one that affects young, lean individuals, who don’t fit either mold? A new wave of research is finally shedding light on this silent and often misdiagnosed condition.

🔍 The YODA Study: A Wake-Up Call from Sub-Saharan Africa

A landmark study published in The Lancet Diabetes & Endocrinology in July 2025—known as the YODA study (Young-Onset Diabetes in Sub-Saharan Africa)—set out to investigate whether children and young adults in Cameroon, Uganda, and South Africa truly had type 1 diabetes, as clinically diagnosed.

What they found was surprising:

• Two-thirds of patients were autoantibody-negative—meaning they didn’t have the immune markers typically seen in type 1 diabetes.

• These individuals were still severely insulin-deficient, but they lacked the signs of insulin resistance seen in type 2 diabetes.

• They also had low genetic risk scores for type 1 diabetes, suggesting a completely different origin.

• Despite being young and lean, they required insulin—but likely not for the reasons doctors assumed.

This wasn’t type 1. It wasn’t type 2.

It wasn’t classic malnutrition diabetes. So what was it?

🆕 Introducing Type 5 Diabetes: A New Subtype, Long Overlooked

In April 2025, the International Diabetes Federation (IDF) announced the formal recognition of a new diabetes subtype: Type 5 diabetes.

Also called malnutrition-related diabetes, this condition develops when early-life undernutrition—often compounded by chronic stress and environmental hardship—impairs the development and function of the pancreas. Over time, this leads to:

• Severe insulin deficiency, but

• Without autoimmune destruction (unlike type 1), and

• Without insulin resistance (unlike type 2).

In other words, the pancreas simply wears out—not from overuse, but from underdevelopment and chronic stress. This aligns remarkably well with what the YODA researchers observed.

🌱 A Bigger Picture: Exposure-Related Malnutrition (ERM)

To understand the full story, we need to zoom out. The pattern seen in the YODA cohort isn’t just about pancreas failure—it’s about how the body adapts under pressure.

This is where the Exposure-Related Malnutrition (ERM) framework comes in.

ERM proposes that chronic exposures—whether from undernutrition, infection, toxins, or psychosocial stress—can slowly reroute how the body allocates energy. Under this model:

• The body prioritizes short-term survival (stress response, blood sugar regulation)

• At the cost of long-term maintenance (growth, repair, and regeneration)

Over time, this trade-off depletes resilience and may lead to functional breakdowns—even if total calories are adequate.

The YODA findings fit this perfectly. These young individuals aren’t just “malnourished” in the traditional sense. They show signs of a bioenergetic collapse, where key systems like the pancreas can no longer keep up. Their insulin deficiency isn’t just a result of disease—it’s a downstream effect of chronic, unresolved adaptation.

🧩 Connecting the Dots

Feature	YODA Cohort	Type 5 Diabetes	ERM Framework
Age	<30 years	Youth/young adults	Affects all ages, but visible early
BMI	Normal or low	Low or normal	Often with low reserve
Autoimmunity	Absent	Absent	Irrelevant; focus is on adaptation
Insulin secretion	Severely reduced	Reduced	Compromised by chronic stress load
Cause	Unknown	Early-life stress/malnutrition	Chronic resource misallocation
Reversibility	Unknown	Possibly modifiable if caught early	Early-stage ERM is reversible

🔄 Why It Matters

Millions of people around the world—especially in low- and middle-income countries—may be misdiagnosed with type 1 or type 2 diabetes, when they’re actually experiencing Type 5 diabetes or an ERM-driven breakdown.

Treating these individuals with standard insulin regimens may not only be inappropriate—it can be dangerous. Instead, they may need:

• Nutritional restoration and metabolic rebuilding

• Stress-reduction and circadian realignment

Most importantly, they need recognition. We can’t treat what we don’t name.

🌍 Toward a New Paradigm

The IDF’s recognition of Type 5 diabetes is a major step forward. But it's just the beginning. We need:

• More research to uncover the full spectrum of ERM-related conditions

• New diagnostic markers that reflect function, not just lab thresholds

• Health systems that understand resilience, adaptation, and repair—not just pathology

The YODA study gave us a glimpse of what happens when the body runs out of options. The ERM framework helps us understand why—and what we can do about it.

🧠 Final Thought

Sometimes, disease isn’t a failure of the body—it’s a sign that the body has been trying to survive for far too long on far too little.

Recognizing this—whether we call it Type 5 diabetes, ERM, or something else—is the first step toward healing, not just treating.

1. Katte, J. C., Squires, S., Dehayem, M. Y., Balungi, P. A., Padoa, C. J., Sengupta, D., ... & Jones, A. G. (2025). Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa: Evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) cross-sectional study. The Lancet Diabetes & Endocrinology. Advance online publication. https://doi.org/10.1016/S2213-8587(25)00120-2

2. International Diabetes Federation. (2025, April 15). IDF announces new Type 5 Diabetes Working Group. https://idf.org/news/new-type-5-diabetes-working-group/

#Type 5 Diabetes, #YODA Study, #Exposure-Related Malnutrition (ERM), #Insulin Deficiency without Autoimmunity, #Stress Adaptation and Metabolic Collapse